FOUR-YEAR OUTCOME OF 215 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB FRONTLINE: A GIMEMA CML WORKING PARTY ANALYSIS

被引：0

作者：

Gugliotta, G. ^{[1
]}

Castagnetti, F. ^{[1
]}

Breccia, M. ^{[2
]}

Levato, L. ^{[3
]}

Fava, C. ^{[4
]}

Luciano, L. ^{[5
]}

Zaccaria, A. ^{[6
]}

Rossi, A. Russo ^{[7
]}

Usala, E. ^{[8
,9
]}

Gozzini, A. ^{[10
]}

Vigneri, P. ^{[11
]}

Cedrone, M. ^{[12
]}

Tiribelli, M. ^{[13
,14
]}

Abruzzese, E. ^{[15
]}

Avanzini, P. ^{[16
]}

Palandri, F. ^{[1
]}

Soverini, S. ^{[1
]}

Alimena, G. ^{[2
]}

Pane, F. ^{[5
]}

Martinelli, G. ^{[1
]}

Cavo, M. ^{[1
]}

Saglio, G. ^{[4
]}

Baccarani, M. ^{[17
]}

Rosti, G. ^{[1
]}

机构：

[1] Univ Bologna, S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[2] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00185 Rome, Italy

[3] Azienda Osped Pugliese Ciaccio, Dept Hematol, Catanzaro, Italy

[4] Univ Turin, San Luigi Gonzaga Hosp, Div Internal Med Hematol, Turin, Italy

[5] Univ Naples Federico II, Dept Hematol CEINGE & Adv Biotechonolgies, Naples, Italy

[6] IRST IRCCS, Hematol Unit, Meldola, Forli Cesena, Italy

[7] Univ Bari, Dept Emergency & Organ Transplantat, Hematol Unit, Bari, Italy

[8] Armando Businco Hosp, Cagliari, Italy

[9] Armando Businco Hosp, Bone Marrow Transplantat Unit, Cagliari, Italy

[10] Univ Florence, Careggi Hosp, Dept Hematol, Florence, Italy

[11] Univ Catania, Ferrarotto Hosp, Div Hematol, Catania, Italy

[12] San Giovanni Hosp, Hematol Unit, Rome, Italy

[13] Univ Udine, Dept Expt & Clin Med Sci, Div Hematol, I-33100 Udine, Italy

[14] Univ Udine, Dept Expt & Clin Med Sci, I-33100 Udine, Italy

[15] S Eugenio Hosp, Dept Hematol, Rome, Italy

[16] Santa Maria Nuova Hosp, Hematol Unit, Reggio Emilia, Italy

[17] Univ Bologna, Bologna, Italy

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P892

引用

页码：333 / 333

页数：1

共 50 条

[21] LONG-TERM OUTCOME OF ALTERNATING NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY AS FRONTLINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A PHASE 2 STUDY OF THE GIMEMA CML WORKING PARTY
Gugliotta, G.
Castagnetti, F.
Breccia, M.
Gozzini, A.
Stagno, F.
Rege-Cambrin, G.
Carella, A. M.
Luciano, L.
Abruzzese, E.
Martino, B.
Usala, E.
Rossi, G.
Bocchia, M.
Cavazzini, F.
Tiribelli, M.
Luatti, S.
Venturi, C.
Soverini, S.
Cavo, M.
Specchia, G.
Alimena, G.
Pane, F.
Martinelli, G.
Saglio, G.
Rosti, G.
Baccarani, M.
HAEMATOLOGICA, 2015, 100 : 131 - 131
[22] IMATINIB MESYLATE IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
Ionita, H.
Ionita, I.
Cheveresan, M.
Iordache, M.
Cheveresan, L.
Ionita, M.
Borzak, G.
Ionita, C. O.
Pascalau, A.
Calamar, D.
Oros, D.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 548 - 548
[23] Nilotinib 800 mg daily as first line treatment of chronic myeloid leukemia in early chronic phase: results of a phase II trial of the GIMEMA CML Working Party
Rosti, G.
Castagnetti, F.
Palandri, F.
Pane, F.
Martinelli, G.
Saglio, G.
Baccarani, M.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[24] NILOTINIB 800 MG DAILY AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN EARLY CHRONIC PHASE: RESULTS OF A PHASE 2 TRIAL OF THE GIMEMA CML WORKING PARTY
Rosti, G.
Castagnetti, E.
Palandri, E.
Breccia, M.
Levato, L.
Capucci, A.
Tiribelli, M.
Alimena, G.
Stagno, F.
Rondoni, M.
Alberti, D.
Marzocchi, G.
Luatti, S.
Amabile, M.
Poerio, A.
Martinelli, G.
Pane, F.
Saglio, G.
Baccarani, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 161 - 161
[25] NILOTINIB 800 MG DAILY IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: 12-MONTHS RESULTS OF A PHASE 2 TRIAL OF THE GIMEMA CML WORKING PARTY
Rosti, G.
Castagnetti, F.
Breccia, M.
Poerio, A.
Gugliotta, G.
Levato, L.
Palandri, F.
Capucci, A.
Tiribelli, M.
Stagno, F.
Marzocchi, G.
Luatti, S.
Amabile, M.
Zaccaria, A.
Alimena, G.
Pane, F.
Martinelli, G.
Saglio, G.
Baccarani, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 440 - 440
[26] Efficacy of Frontline Nilotinib Therapy in Patients. (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP)
Quintas-Cardama, Alfonso
Kantarjian, Hagop M.
Luthra, Rajyalakshmi
O'Brien, Susan
Jabbour, Elias
Borthakur, Gautam
Ravandi, Farhad
Garcia-Manero, Guillermo
Faderl, Stefan
Konopleva, Marina
Wierda, William G.
Burton, Elizabeth
Cortes, Jorge E.
BLOOD, 2011, 118 (21) : 210 - 210
[27] NILOTINIB 400 MG BID AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN EARLY CHRONIC PHASE: RESULTS OF A PHASE 2 TRIAL OF THE GIMEMA CML WORKING PARTY
Castagnetti, F.
Palandri, F.
Poerio, A.
Breccia, M.
Levato, L.
Capucci, A.
Tiribelli, M.
Stagno, F.
Zaccaria, A.
Marzocchi, G.
Luatti, S.
Amabile, M.
Martinelli, G.
Alimena, G.
Saglio, G.
Pane, F.
Baccarani, M.
Rosti, G.
HAEMATOLOGICA, 2008, 93 : S39 - S39
[28] Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
Hagop M. Kantarjian
Timothy P. Hughes
Richard A. Larson
Dong-Wook Kim
Surapol Issaragrisil
Philipp le Coutre
Gabriel Etienne
Carla Boquimpani
Ricardo Pasquini
Richard E. Clark
Viviane Dubruille
Ian W. Flinn
Slawomira Kyrcz-Krzemien
Ewa Medras
Maria Zanichelli
Israel Bendit
Silvia Cacciatore
Ksenia Titorenko
Paola Aimone
Giuseppe Saglio
Andreas Hochhaus
Leukemia, 2021, 35 : 440 - 453
[29] Better molecular response (MR) to imatinib (IM) in early chronic phase (CP) versus late CP chronic myeloid leukemia (CML) patients (pts) in complete cytogenetic response (CCR): A comparison at 24 months of 2 clinical trials of the GIMEMA working party on CML on behalf of the GIMEMA working party on chronic myeloid leukemia (GIMEMA-CML).
Poerio, A
Amabile, M
Iacobucci, I
Soverini, S
Colarossi, S
Ottaviani, E
Terragna, C
Grafone, T
Luatti, S
Castagnetti, F
Pane, F
Saglio, G
Russo, D
Rosti, G
Baccarani, M
Martinelli, G
BLOOD, 2005, 106 (11) : 319A - 319A
[30] Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
Kantarjian, Hagop M.
Hughes, Timothy P.
Larson, Richard A.
Kim, Dong-Wook
Issaragrisil, Surapol
le Coutre, Philipp
Etienne, Gabriel
Boquimpani, Carla
Pasquini, Ricardo
Clark, Richard E.
Dubruille, Viviane
Flinn, Ian W.
Kyrcz-Krzemien, Slawomira
Medras, Ewa
Zanichelli, Maria
Bendit, Israel
Cacciatore, Silvia
Titorenko, Ksenia
Aimone, Paola
Saglio, Giuseppe
Hochhaus, Andreas
LEUKEMIA, 2021, 35 (02) : 440 - 453

← 1 2 3 4 5 →